It should be noted that the 2019 LAM Guidelines do strongly recommend the use of Alere-LAM in all severely ill PLHIV inpatients with TB symptoms, regardless of CD4+ cell count14, which is now aligned with the ART Guidelines’ strong recommendation to initiate ART in all PLHIV regardless of clinical stage or CD4+ cell count30. Here, CD4 is linked to tuberculosis.